scholarly journals A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major

2019 ◽  
Vol Volume 13 ◽  
pp. 2427-2436 ◽  
Author(s):  
Arwa Khaled ◽  
Hoda A Salem ◽  
Dina Ezzat ◽  
Haddel M Seif ◽  
Hoda Rabee
Keyword(s):  
Randomized Controlled Trial ◽  
Pediatric Patients ◽  
Controlled Trial ◽  
Thalassemia Major ◽  
Iron Deposition ◽  
Myocardial Iron ◽  
Randomized Controlled

scholarly journals A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)

Blood ◽  
2014 ◽  
Vol 123 (10) ◽  
pp. 1447-1454 ◽  
Author(s):  
Dudley J. Pennell ◽  
John B. Porter ◽  
Antonio Piga ◽  
Yongrong Lai ◽  
Amal El-Beshlawy ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Ejection Fraction ◽  
Controlled Trial ◽  
Thalassemia Major ◽  
Iron Removal ◽  
Myocardial Iron ◽  
Randomized Controlled ◽  
Key Points

Key Points In β-thalassemia major patients with severe iron burden, deferasirox was noninferior to deferoxamine for myocardial iron removal. The ejection fraction was stable during treatment for both deferasirox and deferoxamine.

The impact of silymarin on antioxidant and oxidative status in patients with β-thalassemia major: A crossover, randomized controlled trial

2017 ◽  
Vol 35 ◽  
pp. 25-32 ◽  
Author(s):  
Hadi Darvishi-Khezri ◽  
Ebrahim Salehifar ◽  
Mehrnoush Kosaryan ◽  
Hossein Karami ◽  
Abbas Alipour ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Thalassemia Major ◽  
Oxidative Status ◽  
Randomized Controlled ◽  
The Impact

Can Use of Silymarin Improve Inflammatory Status in Patients with β-Thalassemia Major? A Crossover, Randomized Controlled Trial

2020 ◽  
pp. 1-8
Author(s):  
Hadi Darvishi-Khezri ◽  
Mehrnoush Kosaryan ◽  
Hossein Karami ◽  
Ebrahim Salehifar ◽  
Mohammadreza Mahdavi ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Thalassemia Major ◽  
Randomized Controlled ◽  
Inflammatory Status

scholarly journals A Pilot Randomized Controlled Trial of Novel Dressing and Securement Techniques in 101 Pediatric Patients

2017 ◽  
Vol 28 (11) ◽  
pp. 1548-1556.e1 ◽  
Author(s):  
Tricia M. Kleidon ◽  
Amanda J. Ullman ◽  
Victoria Gibson ◽  
Brett Chaseling ◽  
Jason Schoutrop ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Pediatric Patients ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Pilot Randomized Controlled Trial

Comparison Of a Powered Bone Marrow Aspiration and Biopsy Device To The Traditional Manual Device In Children

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4980-4980
Author(s):  
Maria G. Falcon-Cantrill ◽  
Paul Thomas ◽  
Victor Saldivar ◽  
Thomas E. Philbeck ◽  
Chatchawin Assanasen
Keyword(s):  
Bone Marrow ◽  
Randomized Controlled Trial ◽  
Research Funding ◽  
Pediatric Patients ◽  
Controlled Trial ◽  
Bone Marrow Aspiration ◽  
Procedure Time ◽  
Randomized Controlled ◽  
Patient Pain ◽  
High Degree

Abstract Background In 2007, a battery powered bone marrow aspiration and biopsy system (OnControl, Vidacare Corp, Shavano Park, TX) was developed and cleared by the US FDA for adult patients.  Multiple studies have evaluated the use of the Powered device in adults and found decreased procedure time, decreased patient pain, improved core biopsy specimens and a higher degree of operator satisfaction compared to traditional Manual Jamshidi-type devices; but there have been no studies demonstrating the system's utility for pediatric patients. In a study sponsored by Vidacare, we conducted a randomized controlled trial to compare the Powered bone marrow aspiration and biopsy system to Manual devices in children. Design/Method A randomized controlled trial was developed to enroll a total of 44 patients between ages 2 and 18 years old requiring a bone marrow evaluation.  Patients were assigned to have a single procedure carried out using the Powered device or the Manual device.  Data were also collected for patients needing bilateral marrow evaluations for direct comparison between the two devices.  The time to obtain the aspirate and biopsy were recorded, as was the pain score post-procedure.  A blinded pathologist recorded the length, width, and overall quality of the specimen.  Operators performing the procedure also completed a survey to evaluate the safety of the device, and their satisfaction with the device. Results  Forty-four patients were enrolled in the study and 5 patients received bilateral procedures; for a total of 49 procedures (Powered n=27, Manual n=22). The mean age was 9.8 (±0.8) years and 60% were male. Statistically, there was no difference in device performance in terms of procedure time, patient pain, operator satisfaction, specimen quality or specimen size. There was a significant difference in perceived device safety and specimen width in favor of the Powered device (p=.034 and p=.027, respectively); and a trend toward significance in terms of operator satisfaction, favoring the Powered device (p=.060). For the Powered device, but not the Manual device, procedure times improved with continued experience, as did biopsy core length and operator satisfaction. There was a significant correlation between level of experience and procedure time. No significant complications were observed using either device. Operators commented that the Powered device was useful when performing procedures on older patients and those with blast-packed marrows. Conclusion   In children, the Powered marrow device may provide benefit over Manual methods as reported in previous adult studies.  We found that the OnControl™ biopsies were obtained with a high degree of safety, with good quality and size, and with a high degree of operator satisfaction.  Such benefits may lead to reductions in anesthesia time and overall costs.  Over time and with more procedures, operators performing procedures noted increased satisfaction and better performance with the Powered device than they did with the Manual device, in both clinical use and ease of training future providers. Disclosures: Falcon-Cantrill: Vidacare Corporation: Research Funding. Off Label Use: Study device (OnControl)is cleared for adult patients, but our study using the device involved pediatric patients. Thomas:Vidacare Corporation: Research Funding. Saldivar:Vidacare Corporation: Research Funding. Philbeck:Vidacare Corporation: Employment. Assanasen:Vidacare Corporation: Research Funding.

Sign in / Sign up

Export Citation Format

Share Document